Announcements
Reviews in Cardiovascular Medicine (RCM) is published by IMR Press from Volume 19 Issue 1 (2018). Previous articles were published by another publisher in Open Access under a CC-BY (or CC-BY-NC-ND) licence, and they are hosted by IMR Press on imrpress.com as a courtesy and upon agreement with MedReviews, LLC.
Open Access
Review
The Drug-Eluting Stent: Is It the Holy Grail?
Show Less
1
Division of Cardiovascular Medicine, Stanford University Medical Center, Stanford, CA
Rev. Cardiovasc. Med. 2001, 2(4), 190–196;
Published: 30 December 2001
Abstract
Although the restenosis rate of coronary stenting is generally 10% to 20%, it
can go as high as 60% in patients with diabetes or complex lesions. Currently,
the only effective treatment for restenosis is brachytherapy. Drug-eluting stents
may be the way to prevent restenosis that cardiologists have been seeking: the
drug-coated stents are simple to use and help prevent negative remodeling and
the intimal hyperplasia caused by stenting. In studies comparing sirolimus-coated
and bare-metal stents, the sirolimus-coated stents resulted in less smooth muscle
cell colonization, minimal intimal hyperplasia, and no edge effect; moreover, no
adverse clinical events were reported. Currently ongoing, multicenter clinical trials
of drug-eluting stents may soon come up with the answers that cardiologists
have been hoping for
Keywords
Restenosis
Intimal hyperplasia
Drug-eluting stent
Sirolimuscoated stent
Bare-metal stent